Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT85JO3)

• DTT Name: 5-HT receptor (5HTR)
• Synonyms: 5-Hydroxytryptamine receptor
• Gene Name: 5HTR
• DTT Type: Successful target; [1]
• BioChemical Class: GPCR rhodopsin
• UniProt ID: NOUNIPROTAC
• TTD ID: T85605

Molecular Interaction Atlas (MIA) of This DTT

6 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[2]
Nafronyl	DMVMQ1L	Cerebrovascular ischaemia	8B1Z	Approved	[1]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[1]
Pizotyline	DMV74ZH	Headache	8A80-8A84	Approved	[1]
Ramosetron	DMH7GN8	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[2]
Tandospirone	DMPHWU6	Anxiety disorder	6B00-6B0Z	Approved	[2]

10 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[3]
ITI-007	DMUQ1DO	Depression	6A70-6A7Z	Phase 3	[4]
EPX-200	DMWK26Q	Dravet syndrome	8A61.11	Phase 2	[5]
EPX-300	DMUXDGZ	N. A.	N. A.	Phase 2	[5]
Lu-AA34893	DM2ZUXK	Anxiety disorder	6B00-6B0Z	Phase 2	[6]
MIN-117	DMSLIW6	Major depressive disorder	6A70.3	Phase 2	[4]
SEP--4199	DMA12HB	Bipolar disorder	6A60	Phase 2	[7]
BF-1	DM7RPSG	Cluster headache	8A81.0	Phase 1	[8]
DSP-6745	DMM86OH	Parkinson disease	8A00.0	Phase 1	[5]
EPX-100	DMXI9P4	Dravet syndrome	8A61.11	Phase 1	[5]

3 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ritanserin	DM0X36Y	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[9]
REV-598	DM314CZ	Carcinoid syndrome	5B10	Terminated	[10]
RGH-2721	DMBCIPO	Psychotic disorder	6A20-6A25	Terminated	[11]

3 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EpiCept	DMFMWA7	Neuropathic pain	8E43.0	Investigative	[12]
MCI	DMZ1YGI	Discovery agent	N.A.	Investigative	[13]
SB 203106	DMQAO5B	Discovery agent	N.A.	Investigative	[14]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
• [7] ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.
• [8] Serotonin (5-HT2B) receptor. SciBX 4(19); doi:10.1038/scibx.2011.534. May 12 2011
• [9] Combined treatment of portal hypertension with ritanserin and propranolol in conscious and unrestrained cirrhotic rats. Hepatology. 1992 May;15(5):878-82.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004008)
• [12] Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108.
• [13] Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest. 2001 Feb;119(2):554-61.
• [14] 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.